Withdrawn application: Jesduvroq, daprodustat, Date of withdrawal: 12/07/2023, Initial authorisation

GlaxoSmithKline Trading Services Limited withdrew its application for a marketing authorisation of Jesduvroq for the treatment of adult patients with symptoms of anaemia caused by chronic kidney disease.

The company withdrew the application on 12 July 2023.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

Withdrawn application: Jesduvroq, daprodustat, Date of withdrawal: 12/07/2023, Initial authorisation

Distribution channels: Healthcare & Pharmaceuticals Industry

EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.